期刊档案

Cancer Screening and Prevention

ISSN 2993-6314 · eISSN 2835-3315 · Xia & He Publishing Inc. · USA · Quarterly · 创刊 2022

Cancer Screening and Prevention 完全开放获取,APC 约 680 美元,出版商公布首次决定约 20 天,录用比例约 58%(社区反馈)。

影响因子—暂无公布值
中科院分区—未被分区表收录
审稿周期20 天出版商公布的投稿到首次决定时间(含直接拒稿)
版面费680 USD完全开放获取
录用比例58%投稿社区平均反馈
年发文量—暂无统计

研究范围

研究范围与定位

Cancer Screening and Prevention (CSP) publishes high-quality research and review articles related to cancer screening and prevention. It aims to provide a platform for studies that develop innovative and creative strategies and precise models for screening, early detection, and prevention of various cancers. Studies on the integration of precision cancer prevention multiomics where cancer screening, early detection and prevention regimens can precisely reflect the risk of cancer from dissected genomic and environmental parameters are particularly welcome.Specifically, CSP publishes epidemiological, translational, and clinical studies on screening, early diagnosis, prevention of various cancers, especially gastrointestinal cancers. Topics of particular interest include but are not limited to:Epidemiology of cancersNew strategies or modelsNovel discoveries of biomarkersNovel devices and clinical applicationInnovative techniques and clinical applicationNovel theories and mechanismsEvidence-based medicineEarly detection of cancerPrecision cancer screening and preventionFuture perspectives The acceptable categories include original article, review article, systematic review, meta-analysis, short communication, letter to the editor, and invited editorial & commentaries on rapidly progressing areas within the scope. All articles published by CSP, both solicited and unsolicited, must have passed a rigorous peer review.

摘自期刊官网 Aims & Scope

主编 Yiqi Du出版商官网

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)未收录

该期刊未被此版本分区表收录。

《新锐期刊分区表》( 2026年3月发布)未收录

该期刊未被此版本分区表收录。

期刊分区表( 2023年12月旧的升级版)未收录

该期刊未被此版本分区表收录。

数据库收录

收录数据库:暂无记录。

国际期刊预警名单:各版本均未列入LetPub

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

Gold OA 文章占比
0%LetPub ·

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

平均审稿速度(社区反馈)
期刊官网数据:平均Median time from submission to first decision: 20 days ; Median time from acceptance to online publishing: 17 days网友分享经验:LetPub ·
平均录用比例(社区反馈)
58%LetPub ·
录用率(出版商公布)
58%出版商官网 ·
投稿到首次决定
20 天出版商官网 ·
评审方式
双盲同行评审出版商官网

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

完全开放获取LetPub

所有文章开放获取,通常向作者收取文章处理费(APC)。

来源文章处理费费用减免许可证观测时间
出版商官网USD 680 / USD 450——

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

投稿准备要点2 项,摘自作者指南
参考文献格式
Vancouver 格式
推荐审稿人
可选
出版商官网 · 模型提取,逐项与原文核对
接收的文章类型15 种,含篇幅限制
  1. case reportCase Reports should describe an individual patient or series of patients (normally less than three) that presented with an unexpected or rare condition that has…正文 ≤ 2,500 词 · 摘要 ≤ 250 词 · 图表 ≤ 4 · 参考文献 ≤ 25
  2. editorial, beginning with “Dear Editor(s),” ~ 10 Editorial ~ 1 ~ 1000 words; Unstructured ~ 10 Case Report Unstructured; No more than 2正文 ≤ 1,000 词 · 图表 ≤ 1 · 参考文献 ≤ 10
  3. hypothesisPlease ensure that any manuscript you submit to CSP conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and the Internation…未说明篇幅
  4. letterPlease ensure that any manuscript you submit to CSP conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and the Internation…正文 ≤ 1,500 词
  5. letter to the editorLetter to the Editor ~ 1 ~ 800 words; Unstructured, beginning with “Dear Editor(s),” ~ 10未说明篇幅
  6. letters to the editorLetters to the Editor should describe timely issues related to a previous publication. These letters should use constructive and professional comments to expand…正文 ≤ 800 词 · 图表 ≤ 1 · 参考文献 ≤ 10
  7. meta-analysisPlease ensure that any manuscript you submit to CSP conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and the Internation…未说明篇幅
  8. mini-reviewMini-review Unstructured; No more than 250 words ~ 2 ~ 3000 words; Structured as Introduction, main body, and Conclusions ~ 70未说明篇幅
  9. opinionation, Discussion, and Conclusions ~ 25 Opinion ~ 2 ~ 1500 words; Unstructured ~ 20 *Word count includes the main body of th正文 ≤ 1,500 词 · 图表 ≤ 2 · 参考文献 ≤ 20
  10. original articleOriginal research manuscripts should describe experimental and/or clinical studies in biomedicine, including exploratory and hypothesis-driven studies of basic …正文 ≤ 5,000 词 · 图表 ≤ 8 · 参考文献 ≤ 50
  11. original researchPlease ensure that any manuscript you submit to CSP conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and the Internation…未说明篇幅
  12. research letterResearch Letter ~ 3 ~ 1500 words; Unstructured ~ 20未说明篇幅
  13. reviewPlease ensure that any manuscript you submit to CSP conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and the Internation…正文 ≤ 3,000 词 · 图表 ≤ 10 · 参考文献 ≤ 300
  14. systematic reviewA systematic review paper, as defined by the Cochrane Collaboration, is a review of a clearly formulated question that uses explicit, systematic methods to iden…正文 ≤ 5,000 词 · 图表 ≤ 8 · 参考文献 ≤ 70
  15. systematic review and meta-analysisSystematic Review and Meta-analysis Structured with Background and objectives, Methods, Results, and Conclusions; No more than 250 words ~ 8 ~ 5000 words; Struc…未说明篇幅
出版商官网
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、许可与版权、开放获取、同行评审、查重、预印本、自存档、试验注册 / 报告规范
AI 使用 Use of AI Tools by Reviewers

该期刊规定,稿件在审稿期间属于保密内容,审稿人不得将未发表的稿件、图表、补充文件、审稿报告或任何与稿件相关的保密信息上传至公开的AI平台。 模型中文摘要

Manuscripts under review are confidential. Reviewers must not upload unpublished manuscripts, figures, tables, supplementary files, review reports, or any confidential manuscript-related information to public AI platforms.

原文 ↗出版商官网 ·
作者资格 Author Contributions

该期刊要求在作者姓名、单位及通讯作者信息之后以段落形式提供作者贡献,并按姓名(以缩写标注)列出每位作者参与研究或稿件撰写的方式,可列为作者的贡献包括研究设计、实验实施、数据分析与解释、稿件撰写、批判性修改、统计分析、经费支持、行政支持以及技术或材料支持。 模型中文摘要

The Authors’ Contributions should be provided in paragraph form following the authors’ names and affiliations and corresponding author(s)’ information. The manner in which each author was involved with the study or preparation of the manuscript is listed with the author’s name (shown as initials, within parentheses). Contributions that are acceptable for inclusion as an author are: study design, p…

原文 ↗出版商官网 ·
利益冲突 Conflict of Interest

该期刊要求所有作者填写ICMJE统一利益冲突披露表,以披露任何潜在的利益冲突,并对所提供信息的准确性和完整性负责。 模型中文摘要

All authors must check the ICMJE’s unified disclosure form. Each author should check the form to disclose any potential conflict of interest and is responsible for the accuracy and completeness of the provided information. The ICMJE’s form can be downloaded here.

原文 ↗出版商官网 ·
数据可用性 Data Sharing Statement

该期刊要求研究类文章提供数据共享声明,以便读者了解如何获取共享数据,并给出了数据已存入知识库、包含在文章内或包含在补充信息文件中等多种示例表述。 模型中文摘要

A Data Sharing Statement is required for research articles through which readers will know how to access the shared data. Sample wording: The [TYPE, such as technical appendix, statistical code, or dataset] data used to support the findings of this study have been deposited in the [NAME] repository ([DOI or other persistent identifier]); The [TYPE] data used to support the findings of this study a…

原文 ↗出版商官网 ·
许可与版权 Copyright

该期刊规定,除非另有说明,已发表文章的版权由作者保留,但作者授予期刊以印刷、出版、销售及其他商业开发等方式出版、复制、展示和存储已发表文章的独家全球权利。 模型中文摘要

The copyright on all published articles will be retained by the authors unless stated otherwise. Authors grant CSP the sole, worldwide, and exclusive right to publish (i.e., print, publish, sell, and otherwise commercially exploit), reproduce, display, and store the published articles.

原文 ↗出版商官网 ·
开放获取 Open Access

该期刊采用开放获取出版模式,所有文章均按CC BY-NC 4.0许可条款发布,允许任何人在正确引用原文的前提下以非商业目的复制、分发或重用文章,且开放获取文章仍须经过与订阅期刊同样严格的同行评审和质量控制。 模型中文摘要

Cancer Screening and Prevention (CSP) adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open a…

原文 ↗出版商官网 ·
同行评审 Peer Review & Editorial Process

该期刊对所有来稿实行双盲同行评审,即作者不知道审稿人身份,审稿人也不知道作者身份,同行评审流程旨在确保研究目标、数据和结论的完整性与透明度,投稿后编辑部会先进行初步评估。 模型中文摘要

The objective of the peer review process is to ensure the integrity and transparency of the research objectives, data, and conclusions.Editorial ProcessAll articles, solicited and unsolicited, that are submitted to CSP will be subject to the following double blind peer review process, meaning that the author does not know the identity of the reviewer, and vice versa.Step 1: Upon submission, the ed…

原文 ↗出版商官网 ·
查重 Types of Plagiarism

该期刊将抄袭定义为在未恰当引用或注明原始出处的情况下使用已发表文献中的信息(包括文字描述、图表和数据),所有投稿稿件都将通过Crossref Similarity Check查重软件进行检测。 模型中文摘要

Plagiarism is defined by the CSP as the use of information, including textual descriptions, figures/tables and data, from a previously published document without proper citation or reference to the original source. All submitted manuscripts will be checked using plagiarism detection software (Crossref Similarity Check).

原文 ↗出版商官网 ·
预印本 Preprint version

该期刊说明预印本是文章经同行评审之前的版本,作者在投稿前无需从非营利预印本服务器上删除预印本,并建议在文章被接收后在首页加入接收致谢。 模型中文摘要

A preprint is the version of an article before peer review. Authors are not requested to remove a preprint from a not-for-profit preprint server before submission. Upon acceptance, we recommend including an acknowledgment of acceptance on the first page, as follows:

原文 ↗出版商官网 ·
自存档 Self-archiving Policy

该期刊允许作者自行存档文章的预印本版本(任何时间),并可在无禁期的情况下自行存档后印本和已发表版本。 模型中文摘要

Authors of articles published in CSP are permitted to self-archive the preprint version of the article at any time, and may self-archive the postprint and published version without embargo.

原文 ↗出版商官网 ·
试验注册 / 报告规范 Study Reporting Guidelines

该期刊要求所有研究者按照相应的EQUATOR研究报告指南撰写文章,原创文章、系统综述、荟萃分析、病例报告和研究方案的投稿须附上相应检查清单,并在投稿时注明所遵循的指南。 模型中文摘要

To enhance the quality and transparency of health research, CSP requires all investigators to prepare articles according to the appropriate EQUATOR research reporting guidelines. Each submission of an original article/systematic review/meta-analysis/case report/study protocol should be accompanied by an appropriate checklist as listed below. Authors can find more guidelines at EQUATOR and should i…

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
Xia & He Publishing Inc.
出版国家或地区
USA
出版语言
English
出版周期
Quarterly
创刊年份
2022
ISSN
2993-6314
电子版 ISSN
2835-3315
官方链接

常见问题

关于 Cancer Screening and Prevention 的常见问题

Cancer Screening and Prevention 的审稿周期多长?

出版商公布的投稿到首次决定时间约为 20 天(首次决定含直接拒稿),平均录用比例反馈为“58%”;期刊官网公布的录用率为 58%。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

Cancer Screening and Prevention 的投稿格式要求是什么?

据期刊作者指南:参考文献格式:Vancouver 格式;推荐审稿人:可选。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。

Cancer Screening and Prevention 是开放获取期刊吗?版面费多少?

Cancer Screening and Prevention 为完全开放获取。APC 约 680 美元。

来源与更新

本页事实来自 LetPub、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。